Melatonin — Coaching

TL;DR

Dosing: 0.5–4 mg; 0.5 mg is nearly as effective as 5 mg for sleep onset. Timing: 2–3 hours before target bedtime — not 30 minutes. Product quality: USP-verified or third-party tested products only; 71% of commercial melatonin fails label within 10%; 26% contain undisclosed serotonin. RBD flag: Consumer wearables cannot diagnose RBD — unusual nocturnal movement requires polysomnography referral, not self-supplementation. Wearable data: Any biometric improvement (SOL, HRV, RHR) from melatonin is proxy-only and individually unreliable.

Why it matters for Vitals

Melatonin is the most evidence-backed over-the-counter sleep-onset intervention. Vitals coaches need to:

1. Correct the #1 usage error: taking melatonin at bedtime (PRC dead zone)
2. Set realistic expectations — melatonin is a circadian signal, not a sedative
3. Flag product quality as a real-world confounder of efficacy
4. Know when to refer (RBD) vs. when to self-manage
5. Interpret wearable data correctly — biometrics alone cannot validate melatonin benefit

Optimal timing

The timing principle

Melatonin taken at bedtime falls in the PRC dead zone — minimal phase-shifting effect. The 2024 dose-response meta-analysis (PMID 38888087) demonstrates that 4 mg administered 3 hours before target bedtime significantly outperforms the commonly recommended 30-minute timing.

For jet lag: Take at destination bedtime (within the advance window), not before travel. Morning light exposure after eastward travel reinforces the phase advance.

For DSPD: Evening melatonin 2–3 hours before target bedtime + morning light therapy. Consistent timing every night for ≥2 weeks is required to entrain the clock.

For general sleep-onset difficulty: Same clock time every night (within the advance window). Consistency matters for circadian entrainment.

Timing summary

Indication	Timing	Notes
Jet lag	At destination bedtime (PM)	Morning light reinforces advance
DSPD	2–3h before target bedtime	Consistent nightly use; 2+ weeks for effect
General sleep onset	2–3h before desired bedtime	Not at bedtime; not in the morning
RBD	Same clock time nightly (~10–11 PM)	Circadian entrainment is the mechanism
Blind free-running rhythm	Same clock time nightly	24h entrainment to external time

Optimal dose

The dose principle

Low doses (0.5 mg) are nearly as effective as high doses (5 mg) for sleep-onset latency. The dose-response curve for sleep onset is relatively flat above ~0.5 mg. Higher doses produce more prolonged blood levels but do not meaningfully improve sleep onset.

Exception: The PRC phase-advance effect may be larger at 3 mg vs. 0.5 mg (PMID 20410229) — relevant for DSPD and jet lag where phase shifting is the therapeutic goal, not just sleep propensity.

Formulation	Dose	Notes
Immediate-release oral	0.5–4 mg	T½ ~45 min; peak at ~1h
Sublingual spray	1 mg	Cmax higher and faster (2,332 pg/mL at ~23 min); shorter duration
PR oral (Circadin® 2 mg)	2 mg	EU/Australia approved for ≥55; T½ ~3.5–4h; better matched to biological night

Vitals-specific dose guidance

• Start low: 0.5 mg; titrate up only if needed
• Product sourcing is the real variable: A correctly-labeled 0.5 mg product may outperform a mislabeled 5 mg product
• Liquid/gummy formulations: Higher stability and content variance risk than tablets/capsules

Product quality guardrails

⚠️ 71% of commercial melatonin products fail to meet label claim within a 10% margin. 26% contain undisclosed serotonin.

Vitals product recommendation:

• USP-verified products (USP mark on label)
• Third-party tested brands with certificates of analysis (CdA) available on request
• Tablet/capsule preferred over liquid/gummy for content stability
• Avoid products marketed as “high-dose” (>10 mg) — GH/anti-aging claims at these doses are unsubstantiated

Serotonin contamination risk: 26% of products contained undisclosed serotonin. This is relevant for:

• Users on SSRIs/SNRIs (serotonin syndrome risk)
• Users with cardiac rhythm concerns
• Users taking other serotonergic compounds

RBD clinical referral flag

⚠️ This is a referral flag, not a coaching decision.

REM Behavior Disorder (iRBD) presents as unusual movement during REM sleep —dream enactment, punching, falling out of bed. It is a prodromal marker for synucleinopathies (Parkinson’s disease, Dementia with Lewy Bodies, Multiple System Atrophy).

Melatonin is first-line treatment for iRBD (PMID 34309908): 2 mg nightly at the same clock time; Ikelos-RS 6.1→2.5; effect maintained at 4.2-year follow-up.

But: Consumer wearables cannot diagnose RBD. If a wearable detects unusual nocturnal movement, or if a user reports dream-enacting behavior:

1. Do not recommend melatonin without clinical evaluation
2. Refer for polysomnography (PSG) — the diagnostic gold standard
3. Self-supplementation without diagnosis delays appropriate neurological workup

The distinction between normal dream-enacting behavior and iRBD requires PSG; no consumer wearable resolves this.

Wearable interpretation

What wearables can and cannot tell us

Consumer wearables cannot detect melatonin ingestion directly. Any biometric inference is proxy-only and not individually validated for melatonin.

Wearable signal	What changes	Confidence	Vitals interpretation
Sleep-onset latency (SOL)	−7 to −17 min at 0.5–5 mg	Moderate (clinical); Low (wearable)	SOL improvement is the most defensible melatonin signal, but effect is within device error for most individuals
Nocturnal HRV (rMSSD)	Lab ECG shows increased HRV	Low (consumer wearable)	Consumer wearable HRV has never been validated for melatonin-specific inference
Resting heart rate	Reduced per RCTs	Low (melatonin-specific)	RHR reduction is non-specific — reflects training, sleep quality, temperature, and many other factors
Sleep staging (REM/N3)	≥5 mg may increase N3/REM in some populations	Not applicable	Consumer wearable sleep staging is unreliable (Apple Watch κ=0.20 vs PSG)

Coaching use of wearable data

Do:

• Use wearable SOL data as one input (alongside self-report) when evaluating whether melatonin is working for a user
• Ask about timing, dose, and dim-light compliance before attributing wearable changes to melatonin
• Recognize that the melatonin’s biometric effect is modest and within night-to-night variability for most users

Do not:

• Attempt to detect melatonin use from wearable data alone
• Use HRV or RHR as compliance signals — these are too non-specific
• Claim wearable data proves melatonin efficacy at the individual level

Cortisol and wearable interpretation

Evening melatonin can normalize elevated nocturnal cortisol in insomnia patients via adrenal MT1 receptors. Morning cortisol (CAR) is not meaningfully suppressed. Elevated nighttime HRV and lower resting HR during melatonin-assisted sleep may reflect improved circadian alignment — but this is a plausible inference, not a validated wearable signal for melatonin specifically.

Vitals product relevance

Melatonin is relevant to Vitals in the following contexts:

• Sleep-onset optimization: The most evidence-backed OTC option for circadian sleep-onset difficulty. Pairs with Magnesium Glycinate and L-Theanine for complementary sleep-onset pathways.
• Jet lag coaching: NNT=2 across ≥5 time zones. Timing at destination is the key coaching intervention.
• Stack context: Melatonin + Magnesium Glycinate + dim-light environment management is the Vitals sleep-onset stack. Sleep Optimization is the broader protocol.
• Detection limits: The melatonin biometric effect is small and confounded — Vitals should not build automated compliance detection for melatonin. Self-report is the appropriate compliance signal.
• Product sourcing: Vitals coaches should direct users to USP-verified or third-party tested products; this is a real-world efficacy variable that biometric data cannot detect.

Comparison to alternatives

Intervention	Melatonin vs. alternative	Bottom line
vs. Trazodone	Melatonin = circadian signal; Trazodone = H1 antagonist sedative	Melatonin preferred for circadian etiology; trazodone for sleep continuity
vs. Diphenhydramine	Melatonin superior safety profile; no tolerance	AASM recommends against diphenhydramine
vs. Magnesium	Complementary mechanisms; both mild	Reasonable stack
vs. Valerian	Melatonin has substantially stronger evidence	AASM recommends against valerian
vs. GABA oral	Oral GABA BBB penetration is pharmacokinetically questionable; melatonin has robust RCT evidence	Melatonin preferred

Related notes

• Melatonin — hub note; full evidence grades, safety table, stack context
• Melatonin — Mechanism — MT1/MT2 receptor biology, PRC, thermoregulation, HPA axis
• Melatonin Sleep Biometrics — biometric signals and their reliability
• Melatonin Detection Model — wearable inference logic and its limits
• Circadian Biology — SCN timing; why timing is the critical variable
• Circadian Light Management — dim-light compliance; light as circadian entraining agent
• Sleep Optimization — broader sleep coaching protocol; melatonin as one lever
• Magnesium Glycinate — complementary sleep-onset stack component
• L-Theanine — complementary calming stack component